JUAN JOSE José EGEA-GUERRERO

Dr. JUAN JOSE José EGEA-GUERRERO


Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2018 in The Lancet
Verified
Journal Article
Open access
NSNikola Sprigg
Nikola Sprigg
KFKatie Flaherty
Katie Flaherty
JAJason P Appleton
Jason P Appleton
RSRustam Al-Shahi Salman
Rustam Al-Shahi Salman
DBDaniel Bereczki
Daniel Bereczki
PBPhilip M Bath
Philip M Bath
Tranexamic acid can prevent death due to bleeding after trauma and post-partum haemorrhage. We aimed to assess whether tranexamic acid reduces haematoma expansion and improves outcome in adults with stroke due to intracerebral haemorrhage. We did an international, randomised placebo-controlled trial in adults with intracerebral haemorrhage from acute stroke units at 124 hospital sites in 12 countries. Participants were randomly assigned (1:1) to receive 1 g intravenous tranexamic acid bolus followed by an 8 h infusion of 1 g tranexamic acid or a matching placebo, within 8 h of symptom onset. Randomisation was done centrally in real time via a secure website, with stratification by country and minimisation on key prognostic factors. Treatment allocation was concealed from patients, outcome assessors, and all other health-care workers involved in the trial. The primary outcome was functional status at day 90, measured by shift in the modified Rankin Scale, using ordinal logistic regression with adjustment for stratification and minimisation criteria. All analyses were done on an intention-to-treat basis. This trial is registered with the ISRCTN registry, number ISRCTN93732214. We recruited 2325 participants between March 1, 2013, and Sept 30, 2017. 1161 patients received tranexamic acid and 1164 received placebo; the treatment groups were well balanced at baseline. The primary outcome was assessed for 2307 (99%) participants. The primary outcome, functional status at day 90, did not differ significantly between the groups (adjusted odds ratio [aOR] 0·88, 95% CI 0·76-1·03, p=0·11). Although there were fewer deaths by day 7 in the tranexamic acid group (101 [9%] deaths in the tranexamic acid group vs 123 [11%] deaths in the placebo group; aOR 0·73, 0·53-0·99, p=0·0406), there was no difference in case fatality at 90 days (250 [22%] vs 249 [21%]; adjusted hazard ratio 0·92, 95% CI 0·77-1·10, p=0·37). Fewer patients had serious adverse events after tranexamic acid than after placebo by days 2 (379 [33%] patients vs 417 [36%] patients), 7 (456 [39%] vs 497 [43%]), and 90 (521 [45%] vs 556 [48%]). Functional status 90 days after intracerebral haemorrhage did not differ significantly between patients who received tranexamic acid and those who received placebo, despite a reduction in early deaths and serious adverse events. Larger randomised trials are needed to confirm or refute a clinically significant treatment effect. National Institute of Health Research Health Technology Assessment Programme and Swiss Heart Foundation.

31 March 2014 in Current Medicinal Chemistry
Verified
Journal Article
Closed access
PDF file
ARAna Rodriguez-Rodriguez
Ana Rodriguez-Rodriguez
JEJUAN JOSE José EGEA-GUERRERO
JUAN JOSE José EGEA-GUERRERO
FMFrancisco Murillo-Cabezas
Francisco Murillo-Cabezas
Antonio Carrillo-VicoAntonio Carrillo-Vico
Antonio Carrillo-Vico
Traumatic brain injury (TBI) is a major healthcare concern, constituting a major cause of death and disability throughout the world. Among the factors leading to TBI outcome are biochemical cascades which occur in response to primary and secondary injury. These mechanisms generate oxidative stress, an imbalance between oxidant and antioxidant agents that can result in neural dysfunction and death. After TBI, an assembly of oxidative stress markers (carbonylated proteins, lipid peroxides, reactive oxygen and reactive nitrogen species) are produced in the brain, while antioxidant defense enzymes decrease (GSH, ratio GSH/GSSG, GPx, GR, GST, G-6PD, SOD, CAT). This imbalance is directly related to the pathogenesis of TBI. Therefore, the development of antioxidant strategies is of primary interest in ongoing efforts to optimize brain injury treatment. The success of any drug intervention strategy relies, in part, on knowledge of the optimal dosage and therapeutic window for its administration. But while the enzymes involved in oxidative stress have been identified, the temporal course of this imbalance following TBI has yet to be determined. This would explain why most antioxidant strategies developed to treat patients with TBI have failed.

1 December 2012 in Clinica Chimica Acta
Verified
Journal Article
Closed access
HMHada Macher
Hada Macher
JEJUAN JOSE José EGEA-GUERRERO
JUAN JOSE José EGEA-GUERRERO
JRJaume Revuelto-Rey
Jaume Revuelto-Rey
EGElena Gordillo-Escobar
Elena Gordillo-Escobar
JEJudy Enamorado-Enamorado
Judy Enamorado-Enamorado
ARAmalia Rubio
Amalia Rubio

1 December 2012 in Clinica Chimica Acta
Verified
Journal Article
Closed access
ARAna Rodríguez-Rodríguez
Ana Rodríguez-Rodríguez
JEJUAN JOSE José EGEA-GUERRERO
JUAN JOSE José EGEA-GUERRERO
ALAntonio León-Justel
Antonio León-Justel
EGElena Gordillo-Escobar
Elena Gordillo-Escobar
JRJaume Revuelto-Rey
Jaume Revuelto-Rey
JGJuan Miguel Guerrero
Juan Miguel Guerrero

7 December 2011 in Brain Injury
Verified
Journal Article
Closed access
PDF file
JEJUAN JOSE José EGEA-GUERRERO
JUAN JOSE José EGEA-GUERRERO
MDMd
Md
JRJ. Revuelto-Rey
J. Revuelto-Rey
FMF. Murillo-Cabezas
F. Murillo-Cabezas
MMM. A. Muñoz-Sánchez
M. A. Muñoz-Sánchez
JLJ. León-Carrión
J. León-Carrión
Introduction: This study tested the hypothesis that S100β is a useful screening tool for detecting intracranial lesion (IL) in patients with a normal level of consciousness after traumatic brain injury (TBI). Methods: One hundred and forty-three post-TBI patients without a decrease in consciousness (GCS = 15) and with at least one neurological symptom (e.g. transitory loss of consciousness, amnesia, headache, dizziness or vomiting) were prospectively included. A blood sample was drawn at 6-hours post-TBI. A routine CT scan was obtained within 24 hours post-injury. Diagnostic properties of S100β for IL prediction in CT scan findings were tested using ROC-analysis. Results: A total of 15 patients (10.5%) had IL. Serum levels were significantly higher in these patients. Significant differences were found between S100β levels and CT scan findings (p = 0.007). ROC-analysis showed that S100β is a useful tool for detecting the presence of IL in CT scans (p = 0.007). In this series, the best cut-off for S100β is 0.130 µg L−1, with 100% sensitivity and 32.81% specificity. Conclusion: Within the first 6 hours post-TBI, serum S100β seems to be an effective biochemical indicator of IL in patients without a decrease in consciousness. These results indicate that higher S100β cut-off values substantially improve the clinical relevance of this protein.

15 October 2013 in Journal of Neurotrauma
Verified
Journal Article
Closed access
JEJUAN JOSE José EGEA-GUERRERO
JUAN JOSE José EGEA-GUERRERO
FMFrancisco Murillo-Cabezas
Francisco Murillo-Cabezas
EGElena Gordillo-Escobar
Elena Gordillo-Escobar
ARAna Rodríguez-Rodríguez
Ana Rodríguez-Rodríguez
JEJudy Enamorado-Enamorado
Judy Enamorado-Enamorado
AVAngel Vilches-Arenas
Angel Vilches-Arenas
Despite improvements in the process of organ donation and transplants, the number of organ donors is progressively declining in developed countries. Therefore, the early detection of patients at risk for brain death (BD) is a priority for transplant teams seeking more efficient identification of potential donors. In the extensive literature on S100B as a biomarker for traumatic brain injury (TBI), no evidence appears to exist on its prognostic capacity as a predictor of BD after severe TBI. The objective of this study is to assess the value of including acute S100B levels in standard clinical data as an early screening tool for BD after severe TBI. This prospective study included patients with severe TBI (Glasgow Coma Scale score [GCS] ≤8) admitted to our Neurocritical Care Unit over a 30 month period. We collected the following clinical variables: age, gender, GCS score, pupillary alterations at admission, hypotension and pre-hospital desaturation, CT scan results, isolated TBI or other related injuries, Injury Severity Score (ISS), serum S100B levels at admission and 24 h post-admission, and a final diagnosis regarding BD. Of the 140 patients studied, 11.4% developed BD and showed significantly higher S100B concentrations ( p <0.001). Multivariate analysis showed that bilateral unresponsive mydriasis at admission and serum S100B at 24 h post-admission had odds ratios (ORs) of 21.35 ( p =0.005) and 4.9 ( p =0.010), respectively. The same analysis on patients with photomotor reflex in one pupil at admission left only the 24 h S100B sample in the model (OR=15.5; p =0.009). Receiver operating characteristics (ROC) curve analysis on this group showed the highest area under the curve (AUC) (0.86; p =0.001) for 24 h S100B determinations. The cut off was set at 0.372 μg/L (85.7% sensitivity, 79.3% specificity, positive predictive value [PPV]=18.7% and negative predictive value [NPV]=98.9%). This study shows that pupillary responsiveness at admission, as well as 24 h serum S100B levels, could serve as screening tools for the early detection of patients at risk for BD after severe TBI.